Immunitybio Inc (IBRX)

Immunitybio Inc (IBRX) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $8.7B; returns 1 day -1.1%, 1 week -10.5%, 1 year +243.9%.

ImmunityBio, Inc. (IBRX) is a commercial-stage biotechnology company focused on developing immunotherapies and cell therapies to treat cancers and infectious diseases. The company's main product is ANKTIVA (nogapendekin alfa inbakicept), an FDA-approved cancer immunotherapy used with BCG to treat BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

Groups IBRX belongs to

• Healthcare
• Biotechnology
• Oncology
• Cancer Therapeutics
• Immunotherapy
• Biopharmaceutical
• Commercial Stage Biotech
• Commercial Stage
• Life Sciences
• Infectious Diseases
• Clinical Stage
• Healthcare Innovation

IBRX financial model: income statement, cash flow and balance sheet